The Cognitive Resilience Study (CogRes)

Duke University

Status: Completed

Conditions: Alzheimer Disease

Treatments: Other: Cognitive stress tests during gait task; Other: Cognitive stress tests during functional MRI

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT03016702

SPS # 224571 (Other Identifier)

Pro00078117

P30AG028716-11S1 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to test whether two new cognitive "stress tests" may help distinguish between people at lower or higher genetic risk of Alzheimer's Disease. The investigators are trying to understand how these cognitive "stress tests" work in people who have not been diagnosed with Alzheimer's Disease and are not exhibiting symptoms of Alzheimer's Disease. Study subjects will undergo testing of memory and executive function during functional magnetic resonance image (fMRI) of the brain and also during a walking test.

Full description

The objective is to establish the feasibility and evaluate the role of two novel tests of cognitive resilience for use in identification of early Alzheimer's Disease. The investigators hypothesize that exposure to the controlled stressor of increased cognitive task demand will evoke measurable phenotypes of poor resilience, which will be associated with Alzheimer's Disease risk. The study will include 30 volunteer participants from the Duke Alzheimer's Disease Prevention Registry (ADPR). The ADPR cohort has been characterized according to genetic risk based on genotype at loci associated with Alzheimer's Disease. The investigators will recruit a sample from the ADPR that includes 15 people in the "genetic high risk" group and 15 people, matched by age, in the "genetic low risk" group. Investigators and experimenters are masked to the genetic profile of all participants. All participants will undergo two cognitive stress test protocols. Both protocols include memory and executive function components, one done during functional MRI and one while ambulating on a force sensor mat. Both cognitive stress tests are minimal risk; the primary risk of this study is loss of confidentiality. Genetic testing is not performed as part of this protocol; the sampling strategy will make use of prior genetic testing results, which are not revealed to the primary investigators. In addition to determining whether scores on the two novel tests statistically differ by AD risk groups, the project will establish the tests' feasibility and characteristics for use in future study.

Enrollment: 29 patients

Sex: All

Ages: 58 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Able to walk 2 minutes without assistive device or assistance from another person
• Cognitive function within normal limits

Exclusion criteria

• Unable to undergo MRI
• Left handed
• Red/Green Color Blind
• Severe vision impairments
• Diagnosis of Alzheimer's Disease or other dementia/memory problem

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

29 participants in 2 patient groups

High Risk Alzheimer's Disease

Experimental group

Description:

This group includes subjects with APOEe4 homozygotes, the genetic profile associated with the highest risk for late-onset AD and the next highest-risk group, APOE e3/e4 heterozygotes. To target the highest risk among the APOEe3/e4 heterozygotes in ADPR, the study team will consider TOMM40-'523 variant status. Although there is uncertainty about the independent role of TOMM40 in AD risk-stratification (especially across racial/ethnic groups), this study will use TOMM40-'523 to guide heterozygote selection based on findings that among e3/e4 heterozygotes, longer TOMM40-523 polyT sequences are associated with earlier age of onset for late-onset AD.

Treatment:

Other: Cognitive stress tests during gait task

Other: Cognitive stress tests during functional MRI

Low Risk Alzheimer Disease

Experimental group

Description:

This group includes e2/e2 homozygotes (rare) and e2/e3 heterozygotes. the genetic profile associated with low risk for late-onset development of Alzheimer's disease.

Treatment:

Other: Cognitive stress tests during gait task

Other: Cognitive stress tests during functional MRI